Archives of dermatology最新文献

{"title":"Editorial: the \"Beauty Doctor\".","authors":"","doi":"10.1001/archdermatol.2012.1022","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.1022","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1354"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.1022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of tattoos with a picosecond alexandrite laser: a prospective trial.","authors":"Nazanin Saedi,&nbsp;Andrei Metelitsa,&nbsp;Kathleen Petrell,&nbsp;Kenneth A Arndt,&nbsp;Jeffrey S Dover","doi":"10.1001/archdermatol.2012.2894","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2894","url":null,"abstract":"<p><p>OBJECTIVE To study a picosecond 755-nm alexandrite laser for the removal of tattoos to confirm the efficacy of this therapy, focusing on the effect of therapy on the target lesion as well as the surrounding tissues and quantifying the number of necessary treatments. DESIGN Fifteen patients with tattoos were enrolled. Treatments were scheduled approximately 6 ± 2 weeks apart. Standard photographs using 2-dimensional imaging were taken at baseline, before each treatment, and 1 month and 3 months after the last treatment. SETTING Dermatology clinic at SkinCare Physicians in Chestnut Hill, Massachusetts. PATIENTS Fifteen patients with darkly pigmented tattoos. MAIN OUTCOME MEASURES Treatment efficacy was assessed by the level of tattoo clearance in standard photographs. These photographs were assessed by a blinded physician evaluator and based on a 4-point scale. Efficacy was also assessed based on physician and patient satisfaction measured on a 4-point scale. RESULTS Twelve of 15 patients with tattoos (80%) completed the study. All 12 patients obtained greater than 75% clearance. Nine patients (75%) obtained greater than 75% clearance after having 2 to 4 treatments. The average number of treatment sessions needed to obtain this level of clearance was 4.25. All 12 patients (100%) were satisfied or extremely satisfied with the treatment. Adverse effects included pain, swelling, and blistering. Pain resolved immediately after therapy, while the swelling and blistering resolved within 1 week. Hypopigmentation and hyperpigmentation were reported at the 3-month follow-up. CONCLUSION The picosecond 755-nm alexandrite laser is a safe and very effective procedure for removing tattoo pigment.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1360-3"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2894","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30912000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis: A Bayesian Network Meta-analysis.","authors":"Vincent W Lin,&nbsp;Sarah Ringold,&nbsp;Emily Beth Devine","doi":"10.1001/2013.jamadermatol.238","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.238","url":null,"abstract":"<p><p>OBJECTIVE To compare the efficacy of ustekinumab with that of other biological agents using the Psoriasis Area and Severity Index (PASI) among adult patients with moderate to severe plaque psoriasis. DATA SOURCES We conducted a systematic search of the period January 31, 1992, to February 1, 2012, using MEDLINE (PubMed), Embase, the Cochrane Library, and clinicaltrials.gov. STUDY SELECTION We included randomized controlled trials of biological agents compared with placebo or other biological agents using the PASI in patients who had moderate to severe plaque psoriasis. DATA EXTRACTION Study data were extracted independently by 2 of us, with disagreement resolved by consensus. Data extracted included the size of the trial, follow-up period, age range of patients, disease duration, body surface area involvement, baseline PASI, PASI response, and previous treatment with biological agents. DATA SYNTHESIS A Bayesian network meta-analysis was performed by fitting 3 regression models: a fixed-effects model, a random-effects model, and a random-effects model with meta-regression coefficients. The random-effects model achieved the best fit for these data. In pairwise comparisons, ustekinumab use was associated with statistically significantly higher odds for achieving a 75% reduction in the PASI compared with adalimumab use (odds ratio [OR], 1.84; 95% credible interval [CrI], 1.01-3.54), alefacept use (OR, 10.38; CrI, 3.44-27.62), and etanercept use (OR, 2.07; 95% CrI, 1.42-3.06) but was associated with lower odds compared with infliximab use (OR, 0.36; 95% CrI, 0.14-0.82) . In the therapeutic class comparison, the interleukin-12/23 inhibitor had the highest odds for achieving a 75% reduction in the PASI compared with placebo (OR, 69.48; 95% CrI, 36.89-136.46), followed by tumor necrosis factor inhibitors (OR, 42.22; 95% CrI, 27.94-69.34) and the T-cell inhibitor (OR, 5.63; 95% CrI, 1.35-24.24). CONCLUSION For the treatment of moderate to severe plaque psoriasis, ustekinumab may be more efficacious than adalimumab, etanercept, and alefacept but not infliximab.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1403-10"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30980304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma.","authors":"Kyle C Mills,&nbsp;Shawn G Kwatra,&nbsp;Ashley N Feneran,&nbsp;Daniel J Pearce,&nbsp;Phillip M Williford,&nbsp;Ralph B D'Agostino,&nbsp;Gil Yosipovitch","doi":"10.1001/archdermatol.2012.3104","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.3104","url":null,"abstract":"Pain is a common feature of cancer with an estimated prevalence rate between 52% and 77%.1 Itch is the most common dermatologic symptom and is also a common feature of lymphoma.2 However, no studies have been performed examining the prevalence rates of pain and itch in common skin cancers. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the 2 most common types of nonmelanoma skin cancer (NMSC). They have a rapidly increasing incidence in the United States, with nearly 4 million new cases of NMSC diagnosed each year.3 The purpose of the present study was to assess the prevalence and intensity of pain and itch among the 2 most common skin cancers.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1422-3"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.3104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.","authors":"Manuelle Viguier,&nbsp;François Aubin,&nbsp;Emmanuel Delaporte,&nbsp;Cécile Pagès,&nbsp;Carle Paul,&nbsp;Marie Beylot-Barry,&nbsp;Catherine Goujon,&nbsp;Michel Rybojad,&nbsp;Hervé Bachelez","doi":"10.1001/2013.jamadermatol.80","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.80","url":null,"abstract":"sults of this study suggest that a simple assessment of pain intensity will aid in the clinical diagnosis of SCC and lead to earlier appropriately aggressive treatment of these lesions. Our subanalysis of the histologic features of these cancers revealed a correlation with perineural invasion and pain. Perineural invasion was identified in 3 cases (2 cases of SCC and 1 case of BCC). While all cases with perineural invasion were painful, the small sample size limits the generalizability of this finding.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1423-5"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.80","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.","authors":"Fatma Cetinözman,&nbsp;Patty M Jansen,&nbsp;Maarten H Vermeer,&nbsp;Rein Willemze","doi":"10.1001/archdermatol.2012.2089","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2089","url":null,"abstract":"<p><p>OBJECTIVE To determine if there are differences in the expression of programmed death-1 (PD-1) between SS and MF, and in particular erythrodermic MF (E-MF). PD-1 is a marker of follicular helper T (TFH) cells and is expressed by the neoplastic T cells of some types of malignant T-cell lymphoma, including mycosis fungoides (MF) and Sézary syndrome (SS). Reported results of PD-1 staining in MF and SS are, however, conflicting. DESIGN Formalin-fixed, paraffin-embedded skin biopsy specimens were stained for PD-1. In addition, PD-1+ cases were stained with antibodies against BCL6, CXCL13, and CD10 to find possible relationship with TFH cells. SETTING Tertiary referral center for cutaneous lymphomas. PATIENTS Twenty-seven patients with SS and 60 patients with MF, including 8 patients with E-MF. RESULTS In patients with SS, expression of PD-1 by more than 50% of the neoplastic T cells was observed in 24 of 27 cases (89%). In contrast, PD-1 expression by more than 50% of neoplastic T cells was found in only 8 of 60 patients with MF (13%), including only 1 of 8 patients with E-MF (12%). In PD-1+ cases, serial skin sections showed that CXCL13 and BCL6 generally stained 25% to 50% of the PD-1+ cells, while expression of CD10 was uncommon. CONCLUSION The results of the present study show differential expression of PD-1 between SS and MF/E-MF, which provides further support for the view that SS and MF are distinct entities.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1379-85"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Violaceous and ulcerated plaque following a cesarean.","authors":"Birka Brauns,&nbsp;Michael P Schön,&nbsp;Hans Peter Bertsch","doi":"10.1001/archdermatol.2012.2964a 10.1001/archdermatol.2012.2964b","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2964a 10.1001/archdermatol.2012.2964b","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1411-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Violaceous and ulcerated plaque following a cesarean section-quiz case.","authors":"Birka Brauns,&nbsp;Michael P Schön,&nbsp;Hans Peter Bertsch","doi":"10.1001/archdermatol.2012.2964a","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2964a","url":null,"abstract":"A 27-year-old woman with a painful, reddish-blue (livedoid) skin area showing small ulcerations on the lower abdomen (Figure 1) was examined. The lesion appeared a few centimeters above the inconspicuous, vertically oriented scar 4 weeks after a cesarean section. A regimen of systemic antibiotics had not been successful. Her medical records revealed a problem with excess weight (body mass index 40 [calculated as weight in kilograms divided by height in meters squared]) and a smoking habit. Laboratory test findings were unrevealing, except for increased antinuclear antibody level (1:160) and a slightly elevated parathyroid hormone level (calcium, phosphate, and vitamin D were within normal levels), which both returned to normal within 6 months. Prothrombotic factors (cryoglobulins and anticardiolipin antibodies) were negative. A biopsy was obtained from a central, nonulcerated region and analyzed with hematoxylin-eosin and CD31 staining (Figure 2 and Figure 3). What is your diagnosis?","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2964a","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32400036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Purpura fulminans from meningococcemia mimicking Stevens-Johnson syndrome in an adult patient taking etanercept.","authors":"Nilanthi D Gunawardane,&nbsp;Kavita Menon,&nbsp;Joan Guitart,&nbsp;Jonathan A Cotliar","doi":"10.1001/2013.jamadermatol.31","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.31","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1429-31"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scaly pruritic plaques in an HIV-positive patient.","authors":"Karolyn A Wanat,&nbsp;Suthinee Rutnin,&nbsp;Carrie L Kovarik","doi":"10.1001/archderm.148.11.1317-c","DOIUrl":"https://doi.org/10.1001/archderm.148.11.1317-c","url":null,"abstract":"A 39-year-old African American man presented with a progressive eruption of fleshy papules on his neck, axillae, groin, and abdomen. The lesions first developed on his neck in his mid-20s and slowly progressed to involve other sites. They occasionally bled when traumatized. His more recent medical history was remarkable for multigland parathyroid hyperplasia, pituitary microadenoma, and neuroendocrine pancreatic tumors. Physical examination revealed dozens of 2to 10mm, flesh-colored to brown, pedunculated, verrucous papules located circumferentially around the neck (Figure 1), extending down to the anterior aspect of the chest, and in the axillae and bilateral groin folds. Scattered across the lower area of the abdomen, there were numerous hypopigmented to flesh-colored 4to 10-mm dome-shaped firmer papules (Figure 2). A 2-cm lightbrown patch was observed on the left upper arm area. There was also mild freckling around the posterior axillary folds. Punch biopsy specimens were obtained from a pedunculated papule on the neck and a dome-shaped papule on the abdomen. What is your diagnosis?","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 11","pages":"1317-8"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archderm.148.11.1317-c","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31060160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}